| INTRODUCTION
Congenital diarrheal disorders (CDD) represent heterogeneous enteropathies, typically presenting with unremitting diarrhea in the first few months of life. [1] [2] [3] These diarrheal syndromes are predominately caused by inherited, autosomal recessive mutations that result in secretory or osmotic diarrhea, requiring significant dietary modification, total parental nutrition supplementation and, in rare cases for diseases such as MVID, intestinal transplantation. If unrecognized, patients can suffer from profound dehydration, multiorgan failure, and death. 3 Recent work has categorized these diseases into four groups based on the cellular defect caused by a respective mutation: absorption and transport of nutrients and electrolytes, enterocyte differentiation and polarization, enteroendocrine cell differentiation, and modulation of the intestinal immune response. 3 While the identification of the disease-associated genes aid diagnosis and disease management in patients, understanding the functionality of the mutations will allow for screening of new therapeutic targets.
The DGAT1 gene resides on human chromosome 8 and encodes diacyl CoA: diacylglycerol acyl transferase (DGAT), the enzyme responsible for catalyzing the final step in triglyceride synthesis, using diacylglycerol (DAG) and fatty acyl CoA. 4 Mutations in this gene result in significant protein losing enteropathy, first described in two siblings born to non-consanguineous Ashkenazi Jewish parents. 5 Both children were homozygous for a splice site mutation, resulting in the deletion of 25 amino acids and loss of DGAT1 function. 5 These patients presented with diarrhea within the first week of life, hypoalbuminemia and hypertriglyceridemia. Two additional missense mutations were described in three children, all with less severe symptomatology. One child with a mutation in the membrane-bound O-acyl transferase domain of DGAT1 presented slightly later in life (2-4 months) without triglyceride abnormalities, while two twins of South Asian descent were found to have a p.L105P missense mutation resulting in partial loss of function, hypertriglyceridemia and a delay in symptom onset and severity. 6, 7 Most recently, 10 further patients with 5 different biallelic mutations have been reported with varying degrees of intestinal failure and variable onset of symptoms. 8 These findings expand the clinical and molecular characteristics of DGAT1 deficiency and suggest variations in enzyme deficiency may drive a wider, unrecognized spectrum of congenital diarrhea phenotypes.
While DGAT1 deficiency falls into the second group of congenital diarrheal disease, that is, defects in enterocyte differentiation and polarization, this classification is fairly arbitrary without an understanding of the mechanism by which DGAT1 deficiency drives diarrhea. DGAT1 knockout mice are noted to be lean, resistant to obesity and hypertriglyceridemia, making DGAT1 inhibition an attractive pharmacologic target for treatment of obesity. 4, 9 Yet when transitioned to human trials, the dose and tolerability of DGAT1 inhibitors was limited due to diarrhea, nausea and vomiting, interestingly, follows a similar profile to the symptoms experienced with infants with congenital DGAT1 mutations. [10] [11] [12] The cause of diarrhea following DGAT1 loss remains unknown. Whole exome sequencing was performed for the patient at 3 years of age, revealing a homozygous mutation in DGAT1 (chromosome 8, 145541756 A ! G) in the splice donor site 3 0 of exon 8, altering the invariant GT to GC (Figure 2 ). This mutation was the same mutation in the two patients reported initially. 5 The patient's mother was heterozygous for the mutation (Figure 2 ).
Following identification of his homozygous DGAT1 mutation, based on the success reported in the original case report, 5 the patient was switched to a very low-fat diet (Tolerex formula) resulting in the resolution of his diarrhea and discontinuation of his TPN requirement within 2 months. He showed dramatic improvement in his growth and height ( Figure 1B) , and at the time of this writing has not been admitted to the hospital in the 2 years since transitioning to the fatrestricted diet.
| Loss of apical transporters and dysfunction of polarity
Initial biopsies of the patient were reviewed to confirm the diagnosis of DGAT1 deficiency, with notable loss of immunostaining for DGAT1
in the patient's duodenal tissue when compared to control ( Figure 3A ). Given previous work suggesting significant defects in intestinal apical transporters associated with congenital diarrheal diseases, we performed immunofluorescence staining of biopsy sections Figure 4D ). In addition, in the biopsy at 13 months of age, subapical vesicular accumulations were observed in some groups of enterocytes. These vesicles often were located directly below the apical surface ( Figure 4E ,F).
A hallmark of DGAT1 diarrhea is the profound protein losing enteropathy of unknown etiology in these patients. This diagnosis was shared by our patient, who suffered from persistent hypoalbuminemia during his first few months of life. Using TEM, we focused our attention on junctional integrity of the patient's tissue ( Figure 4G ).
Multiple, expanded tight and adherens junctions were present in the lateral membranes in the duodenal enterocytes.
To evaluate further the integrity of the tight junctions and the ability of enterocytes to establish these junctions in the setting of apparent altered polarity, we immunostained for Claudin 4 (CLDN4), JAM, and occludin. While these proteins localized to the apical and apicolateral border of enterocytes in control neonatal tissue, they were grossly redistributed in the DGAT1 mutant patient. In the case of JAM1 and occludin, there was a decrease in immunostaining in the apical junctional area with redistribution to the basal lateral membrane as well as cytoplasmic relocalization of these junctional markers ( Figure 4H ). Basolateral markers, including E-cadherin and p120, remained unchanged (data not shown). 
| In vitro knockdown of DGAT1 expression in Caco2-BBe cells models apical trafficking dysfunction
To examine the effects of the loss of DGAT1 on the establishment of apical polarity, we stably knocked down DGAT1 expression in
Genotyping of patient and mother. To confirm the diagnosis of DGAT1 mutation, Sanger sequencing was performed on the region of DNA amplified from a control human DNA sample and DNA isolated from blood from the patient and his mother. The Sanger sequencing showed that the mother was heterozygous for the mutation while the patient was homozygous However, instead of forming a smooth internal hollow ball, the apical surface transitioned throughout the center of the cyst. When single cysts were selected for closer evaluation, DPPIV appeared to collect around multiple cystic structures within the cyst, unable to present a clear, polarized lumen when compared to control cells ( Figure 6 ). When we stained the cysts for occludin (Figure 6 ), the controls exhibited the typical apical lateral junction staining pattern, while the DGAT1 knockdown cysts had a decrease at the apical lateral junctions with occludin now found at the basal lateral junction (arrows in Figure 6B ), similar to the pattern observed in the patient with the DGAT1 mutation.
| Exposure to extremely low-fat media ameliorates the phenotype in DGAT1-KD cells
We also evaluated the behavior of DGAT1-KD on permeable Transwell filters. The DGAT1-KD and Scrambled control Caco-2BBe cell lines were grown for 7 days post-confluence. This study describes the presentation, work up, diagnosis and treatment of one such congenital diarrhea case. Whole exome sequencing of the patient with enteropathy confirmed a loss of function mutation in DGAT1 identical to the mutation originally described in two Ashkenazi Jewish siblings. 5 The delayed onset of symptoms Our patient was transitioned to the very low-fat enteral formula, Tolerex, which contains 2% of calories from fat. Previous reports describe successful treatment with anywhere from 4% to 10% calories from fat, yet given this rare disease and limited literature, much of the dietary intervention is based on experience with a handful of diagnosed patients. 5, 6 The processing of fat is far more complex, and while DGAT1 loss is known to affect triglyceride levels and has been described as creating hypertriglyceridemia, this was not observed in either our patient, or in the patients with p.L105P mis-sense mutation. 6 To model DGAT1 loss in vitro, we successfully knocked down porters to the apical membrane. 15 Thus, in our patient, the recovery of apical trafficking to the brush border of enterocytes at the villus FIGURE 6 Knockdown of DGAT1 in Caco2-BBe cells grown in a 3D matrix alters the newly formed apical membrane. The Caco2-BBe control (top row) and the DGAT1-KD (rows 2 and 3) cell lines were grown for 7 days as 3D cultures in Matrigel. (A) The cysts were stained for DDPIV (green in merge), DGAT1 (red in merge), F-actin (cyan in merge) and DAPI (blue in merge). The majority (88%) of the controls exhibited a smooth round central lumen with apical DPPIV and F-actin, while only a small subset of the DGAT1 knockdown cysts exhibited a central lumen (28%) with the majority exhibited a scrambled lumen (72%). (B) The cysts were stained for DDPIV (green in merge), DGAT1 (red in merge), Occludin (cyan in merge) and F-actin (blue in merge). Arrowheads indicate DPPIV, occludin and F-actin at the basal lateral junction. Bar = 10 μM tips following very low-fat enteral feeding may accrue from reduced levels of intracellular diacylglycerol and normalization of intracellular phospholipid pools. We also observed recovery of DPPIV and occludin in the Caco-2BBe DGAT1-KD cell line when the cells were transferred to extremely low-fat media, indicating that the Caco-2BBe
DGAT1-KD cells can be used a model system for the disease. These Fastqs were aligned to the human reference genome GRCh37 using BWA version 0.6.2. Bams were then cleaned and realigned using GATK2 Best Practices. Variant calling was performed and the VCF file was uploaded into Fabric Enterprise (formerly Omicia, Fabric Genomics) for variant analysis.
| Sanger sequencing
For Sanger sequencing confirmation of the mutation, genomic DNA purified from blood as above from the patient, his mother and a normal control were used to amplify and sequence the region around the putative mutation. In Brief, 1 μL of purified DNA was utilized in a PCR reaction with Accuprime Pfx Mix (Agilent) using specific sense (ctcccactctgctgtgctcgtagcctc) and anti-sense (gaggaagtagtagagatctggaatgggaatg) primers with 42 cycles of amplification (95C 30s, 60C 30s, 68C 40s). The resulting fragments were resolved on a 1% agarose gel, isolated (Qiagen) and submitted for sequencing with both the sense and anti-sense primers.
| Cell lines, real-time PCR analysis, lentivirusmediated DGAT1-KD
Human colonic epithelial Caco2-BBe cell lines were grown in DMEM. 
| Human tissue preparation
Samples of duodenum from the patient with DGAT1 deficiency were obtained via endoscopic biopsies. All tissue samples were obtained through protocols approved by the Vanderbilt University Medical
Center IRB. All biopsy samples were washed in PBS and fixed in 10%
formalin. Samples were stored in 70% ethanol, embedded in paraffin, and sectioned for immunostaining. 
| Transmission electron microscopy

| Sectioning and imaging
A total of 500 to 1000 nm thick sections were cut for ultra-structure Table 1 ). The next day the cysts were 
| Histology
Normal human duodenum sections and those from the patient with the DGAT1 mutation were deparaffinized and were submitted to antigen retrieval in a pressure cooker using the target retrieval solution Table 1 . Tissue sections were washed 3 times in PBS and mounted with ProLong Gold plus DAPI (Invitrogen). All imaging was performed using the Olympus FV-1000 or Zeiss Axiophot microscope equipped with an Axiovision digital imaging system (Zeiss, Jena GmBH).
| Lipid analysis
Three hundred microliters of ice-cold PBS (10× diluted) was added to an Eppendorf tube which contained either the Caco-2BBe control or DGAT1 knockdown cells. Individual cell suspensions were homogenized for 1 minute using a disposable soft tissue homogenizer. An aliquot of 25 μL was pipetted to determine the protein content (BCA protein assay kit, Thermo Scientific). The rest of homogenate was accurately transferred into a disposable glass culture test tube, and a mixture of lipid internal standards was added prior to lipid extraction for quantification of all reported lipid species. Lipid extraction was performed by using a modified Bligh and Dyer procedure as described previously. 22 Each lipid extract was resuspended into a volume of 500 μL of chloroform/methanol (1:1, v/v) per mg of protein and flushed with nitrogen, capped, and stored at −20 C for lipid analysis.
Part of the lipids extract was taken out to be derivatized with DMG (dimethylglycine) for DAG analysis as described. 23 For ESI direct infusion analysis, lipid extracts or DAG derivatives
were further diluted to a final concentration of~500 fmol/μL, and the mass spectrometric analysis was performed on a QqQ mass spectrometer (Thermo TSQ VANTAGE) equipped with an automated nanospray device (TriVersa NanoMate, Advion Bioscience Ltd.) as described. 24 Identification and quantification of lipid species from mass spectrometric analysis were conducted as previously described. 25 
